全球迷走神经刺激市场：依产品、生物材料、应用、地区、范围和预测

全球迷走神经刺激市场规模及预测

2024 年全球迷走神经刺激市场规模价值 106.7 亿美元，预计到 2031 年将达到 237.3 亿美元，2024 年至 2031 年的复合年增长率为 10.50%。迷走神经刺激 (VNS) 是一种神经调节疗法，它会向迷走神经发送电脉衝来治疗多种疾病，包括癫痫和忧郁症。这种治疗方法可以调节神经通路和神经传导物质的释放，从而改善情绪并减少癫痫发作频率。

VNS 的应用范围已不仅限于癫痫和忧郁症，目前研究也在探索其在治疗焦虑症、慢性疼痛和发炎性疾病方面的潜力。

技术的进步和对神经迴路的理解可能会带来更精确、更有效的刺激方法、个人化治疗和非侵入性替代方法的开发，最终改善患者的治疗效果，因为它将改善治疗效果并扩大各种健康问题的治疗选择。

全球迷走神经刺激市场动态

主要市场驱动因子

神经系统疾病发生率不断上升：

癫痫和忧郁症等神经系统疾病的发生率不断上升，推动了对 VNS 的需求。根据世界卫生组织 (WHO) 的数据，全球约有 5,000 万人患有癫痫，其中近 30% 患有难治性癫痫，这增加了对替代疗法的需求。

神经调节疗法的传播：

医疗保健提供者对神经调节疗法的接受度不断提高，从而推动了市场的成长。根据美国国立卫生研究院的报告，包括 VNS 在内的神经调节技术反映了向创新治疗方法的转变，全球约有一百万名患者采用了这些技术。

VNS 设备的技术进步：

VNS 技术的不断进步，包括小型化和设备功效的提高，正在改善患者的治疗效果。美国食品药物管理局 (FDA) 报告称，神经调节疗法设备批准的年增长率为 6.5%，显示 VNS 创新管道强劲。

增加医疗支出：

医疗保健支出的增加正在推动对包括 VNS 设备在内的先进医疗技术的投资。根据美国医疗保险和医疗补助服务中心 (CMS) 的数据，美国的医疗保健支出预计到 2028 年将达到 6.2 兆美元，这为 VNS 和其他神经调节疗法的发展创造了肥沃的环境。

主要问题

设备和程式成本高

VNS 设备和植入程序的高成本可能会限制其可近性，尤其是对于低收入地区的患者。这一经济障碍影响了 VNS 治疗的采用率。

对医疗保健提供者的认知有限

一些医疗保健提供者仍然缺乏对VNS的认识和理解，这可能会阻止他们将其推荐为治疗选择。需要进行教育工作来增加人们对这种治疗益处的认识和理解。

患者反应

并非所有患者对 VNS 的反应都很好，且治疗结果也各不相同。这种不一致使得医疗保健提供者和患者对治疗的有效性产生不确定性。

监理障碍

医疗器材监管环境复杂且耗时。监管课题可能会延迟新 VNS 技术的批准，从而影响市场成长和创新。

主要趋势：

转变为非侵入性 VNS 的

非侵入性迷走神经刺激 (VNS) 方法的发展趋势日益明显，例如经皮迷走神经刺激，它可以为患者提供一种比传统手术更简单、风险更低的替代方法。

整合人工智慧

将人工智慧和机器学习融入 VNS 系统可以根据个别患者数据实现更个人化的刺激参数，从而有可能提高治疗效果。

扩展到新的适应症

越来越多的研究正在探讨迷走神经刺激(VNS) 对一系列疾病的治疗潜力，这些疾病不仅包括癫痫和忧郁症，还包括焦虑症、偏头痛和发炎性疾病，从而扩大了这种治疗方法的应用范围。

联合研究计画

学术机构、医疗保健提供者和行业利益相关者之间的合作正在增加，透过共享知识和资源来促进创新和新 VNS 技术和治疗方案的开发。

目录

第 1 章全球迷走神经刺激市场：简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章迷走神经刺激的全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会

第5章 全球迷走神经刺激市场（依产品）

• 概述
• 植入式迷走神经刺激装置
• 外部 VNS 设备

第6章全球迷走神经刺激市场（依生物材料）

• 概述
• 聚合物
• 金属
• 陶瓷

第7章 全球迷走神经刺激市场（按应用）

• 概述
• 忧郁症
• 偏头痛
• 癫痫
• 其他

第8章 全球迷走神经刺激市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 9 章迷走神经刺激市场：竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第10章 公司简介

• LivaNova Plc.
• Medtronic Plc.
• EnteroMedics Inc.
• ElectroCore LLC
• Boston Scientific Corporation
• NeuroPace Inc
• BioControl Medical
• Bioness Inc.
• Nevro Corporation
• Aleva Neurotherapeutics SA.

第 11 章附录

• 相关研究

Global Vagus Nerve Stimulation Market Size and Forecast

The Global Vagus Nerve Stimulation Market size was valued at USD 10.67 Billion in 2024 and is projected to reach USD 23.73 Billion by 2031 , growing at a CAGR of 10.50% from 2024 to 2031. Global Vagus Nerve Stimulation (VNS) is a neuromodulation therapy that involves delivering electrical impulses to the vagus nerve to treat various medical conditions, particularly epilepsy and depression. This technique works by modulating neural pathways and neurotransmitter release, which can lead to improved mood and reduced seizure frequency.

The application of VNS has expanded beyond epilepsy and depression, with research exploring its potential in treating conditions such as anxiety disorders, chronic pain, and inflammatory diseases.

The future of Global VNS looks promising, as advancements in technology and understanding of neural circuits could lead to more precise and effective stimulation methods, personalized therapies, and non-invasive alternatives, ultimately enhancing patient outcomes and expanding treatment options for diverse health challenges.

Global Vagus Nerve Stimulation Market Dynamics

The key market dynamics that are shaping the global vagus nerve stimulation market include:

Key Market Drivers:

Increasing Prevalence of Neurological Disorders:

The rising incidence of neurological disorders such as epilepsy and depression drive the demand for VNS. According to the World Health Organization (WHO), approximately 50 million people worldwide have epilepsy, with nearly 30% of these individuals experiencing drug-resistant seizures, highlighting a significant need for alternative treatments.

Growing Adoption of Neuromodulation Therapies:

The increasing acceptance of neuromodulation therapies among healthcare providers is propelling market growth. A report from the National Institute of Health estimated that neuromodulation techniques, including VNS, have been adopted in about 1 million patients globally, reflecting a shift toward innovative therapeutic approaches.

Technological Advancements in VNS Devices:

Continuous advancements in VNS technology, such as miniaturization and improvements in device efficacy, are enhancing patient outcomes. The U.S. Food and Drug Administration (FDA) reported a 6.5% annual growth rate in device approvals for neuromodulation therapies, indicating a robust pipeline for VNS innovations.

Rising Healthcare Expenditure:

Increased healthcare expenditure is driving investments in advanced medical technologies, including VNS devices. According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending is projected to reach $6.2 trillion by 2028, which fosters an environment conducive to the growth of VNS and other neuromodulation therapies.

Key Challenges:

High Cost of Devices and Procedures

: The high cost associated with VNS devices and implantation procedures can limit accessibility for patients, especially in low-income regions. This financial barrier affects the adoption rate of VNS therapies.

Limited Awareness Among Healthcare Providers

: There is still a lack of awareness and understanding of VNS among some healthcare providers, which can hinder its recommendation as a treatment option. Educational initiatives are needed to enhance knowledge and understanding of the therapy's benefits.

Variable Patient Response

: Not all patients respond favorably to VNS, leading to variability in treatment outcomes. This inconsistency can create uncertainty among healthcare providers and patients regarding the effectiveness of the therapy.

Regulatory Hurdles

: Navigating the regulatory landscape for medical devices can be complex and time-consuming. Regulatory challenges may delay the approval of new VNS technologies, impacting market growth and innovation.

Key Trends:

Shift Towards Non-Invasive VNS

: There is a growing trend toward developing non-invasive VNS methods, such as transcutaneous vagus nerve stimulation, which can provide patients with easier and less risky alternatives to traditional surgical options.

Integration of Artificial Intelligence

: The incorporation of artificial intelligence and machine learning into VNS systems is emerging, allowing for more personalized stimulation parameters based on individual patient data, which could enhance treatment efficacy.

Expansion into New Indications

: Research is increasingly exploring the potential of VNS for various conditions beyond epilepsy and depression, including anxiety, migraine, and inflammatory diseases, indicating a broader application scope for this therapy.

Collaborative Research Initiatives

: Collaborative efforts among academic institutions, healthcare providers, and industry stakeholders are on the rise, fostering innovation and the development of new VNS technologies and treatment protocols through shared knowledge and resources.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Vagus Nerve Stimulation Market Regional Analysis

Here is a more detailed regional analysis of the global vagus nerve stimulation market:

North America:

North America holds a dominant position in the global vagus nerve stimulation market, accounting for a significant share due to advanced healthcare infrastructure and high adoption of innovative medical technologies. The presence of key players, robust research and development activities, and strong support from healthcare policies further contribute to the market's growth in this region. According to the U.S. Centers for Disease Control and Prevention (CDC), the prevalence of neurological disorders, which can be treated with vagus nerve stimulation, is expected to rise, enhancing the demand for such therapeutic interventions.

Moreover, the increasing incidence of epilepsy and depression, conditions where vagus nerve stimulation has proven effective, drives the market in North America. The National Institute of Neurological Disorders and Stroke (NINDS) reported that approximately 1 in 26 individuals will develop epilepsy at some point in their lives, indicating a significant patient population that could benefit from these treatments. This substantial demand for effective management solutions has led to higher investments in vagus nerve stimulation technology by both healthcare providers and pharmaceutical companies.

Asia Pacific:

The Asia Pacific region is the fastest-growing market for vagus nerve stimulation. Factors such as the increasing prevalence of neurological disorders, growing awareness of advanced treatment options, and a rapidly expanding healthcare sector drive this growth. According to the World Health Organization (WHO), Asia Pacific is home to over 60% of the global population, highlighting a substantial potential market for innovative medical treatments.

The region is experiencing a surge in investment in healthcare infrastructure, with governments actively promoting advanced medical technologies. For instance, the Indian government has initiated various healthcare reforms aimed at improving access to cutting-edge treatments, including those for neurological disorders. According to a report from the Ministry of Health and Family Welfare, investments in mental health and neurological care are projected to grow by 20% annually, supporting the increased adoption of vagus nerve stimulation therapies across the region.

Global Vagus Nerve Stimulation Market: Segmentation Analysis

The Global Vagus Nerve Stimulation Market is segmented on the basis of By Product, By Biomaterial, By Application, and By Geography.

Global Vagus Nerve Stimulation Market, By Product

• Implantable VNS Devices
• External VNS Devices

Based on Product, the Global Vagus Nerve Stimulation Market is segmented into Implantable VNS Devices and External VNS Devices. Implantable VNS Devices is the dominating segment due to their established efficacy and long-term therapeutic benefits, particularly for conditions such as epilepsy and treatment-resistant depression. However, the fastest-growing segment is the external VNS devices, primarily driven by their non-invasive nature, ease of use, and growing consumer preference for less invasive treatment options.

Global Vagus Nerve Stimulation Market, By Biomaterial

• Polymerics
• Metallics
• Ceramics

Based on Biomaterial, the Global Vagus Nerve Stimulation Market is segmented into Polymerics, Metallics, and Ceramics. The Polymerics is the dominating segment due to its versatile applications across various industries, including automotive, packaging, and consumer goods, driven by properties such as lightweight, corrosion resistance, and cost-effectiveness. However, the ceramics segment is recognized as the fastest-growing segment, largely attributed to the increasing demand for advanced ceramics in applications such as electronics, healthcare, and aerospace, where their high thermal stability and mechanical strength are essential.

Global Vagus Nerve Stimulation Market, By Application

• Depression
• Migraine
• Epilepsy

Based on Application, the Global Vagus Nerve Stimulation Market is segmented into Depression, Migraine, and Epilepsy. The Epilepsy is the dominating segment due to its established application in treating drug-resistant epilepsy, supported by robust clinical evidence and FDA approval for VNS devices. However, the fastest-growing segment is depression, as there is increasing recognition of VNS as an effective treatment for treatment-resistant depression.

Global Vagus Nerve Stimulation Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Vagus Nerve Stimulation Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America is the dominant region, accounting for a significant share due to advanced healthcare infrastructure and high adoption of innovative medical technologies. Asia Pacific region is the fastest-growing market for vagus nerve stimulation. Factors such as the increasing prevalence of neurological disorders, growing awareness of advanced treatment options, and a rapidly expanding healthcare sector drive this growth.

Key Players

• The "Global Vagus Nerve Stimulation Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market
• LivaNova Plc., Medtronic Plc., EnteroMedics Inc., ElectroCore LLC, Boston Scientific Corporation, NeuroPace Inc, BioControl Medical, Bioness Inc., Nevro Corporation, and Aleva Neurotherapeutics SA.
• Our
• market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
• Global Vagus Nerve Stimulation Market: Recent Developments
• In August 2024 ElectroCore, Inc. announced the acquisition of a complementary neuromodulation technology company to enhance its product portfolio in the vagus nerve stimulation market.
• In July 2024 LivaNova PLC received FDA approval for the expanded use of its Vagus Nerve Stimulator (VNS) device for treatment-resistant depression.
• In June 2024 NeuroMetrix, Inc. announced positive results from a clinical study evaluating the efficacy of its non-invasive vagus nerve stimulation device for chronic pain management.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VAGUS NERVE STIMULATION MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VAGUS NERVE STIMULATION MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities

5 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Implantable VNS Devices
• 5.3 External VNS Devices

6 GLOBAL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL

• 6.1 Overview
• 6.2 Polymerics
• 6.3 Metallics
• 6.4 Ceramics

7 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Depression
• 7.3 Migraine
• 7.4 Epilepsy
• 7.5 Others

8 GLOBAL VAGUS NERVE STIMULATION MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL VAGUS NERVE STIMULATION MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 LivaNova Plc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Medtronic Plc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 EnteroMedics Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 ElectroCore LLC
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Boston Scientific Corporation
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 NeuroPace Inc
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 BioControl Medical
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Bioness Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Nevro Corporation
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Aleva Neurotherapeutics SA.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research